Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | blood | Geigy Scientific Tables, 8th Rev edition. Edited by C. Lentner, West Cadwell, N.J.: Medical education Div., Ciba-Geigy Corp., Basel, Switzerland c1981-1992. | ||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
|||
NPO24062 | Radix pseudostellariae | Species | Lymnaeidae | Eukaryota | TCMID* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT2 | Others | Unspecified | IC50 | = | 100000 | nM | 8709123 | |
NPT2 | Others | Unspecified | IC50 | = | 5000 | nM | 8709123 | |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | Ratio EC50 | = | 1000 | 16942026 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 110 | 16942026 | |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 88000 | nM | 16942026 |
NPT4375 | Individual Protein | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | Burkholderia pseudomallei (strain K96243) | Kd | = | 75000 | nM | 24157367 |
NPT4376 | Individual Protein | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | Escherichia coli (strain K12) | Inhibition | = | 46 | % | 23509611 |
NPT4376 | Individual Protein | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | Escherichia coli (strain K12) | IC50 | = | 768000 | nM | 23509611 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC120887 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9888 | High Similarity | NPC328779 |
0.9886 | High Similarity | NPC6166 |
0.9886 | High Similarity | NPC226769 |
0.9886 | High Similarity | NPC280946 |
0.967 | High Similarity | NPC328914 |
0.9556 | High Similarity | NPC90240 |
0.9551 | High Similarity | NPC329384 |
0.9091 | High Similarity | NPC62927 |
0.9091 | High Similarity | NPC190334 |
0.875 | High Similarity | NPC229249 |
0.8229 | Intermediate Similarity | NPC283698 |
0.8229 | Intermediate Similarity | NPC73765 |
0.8172 | Intermediate Similarity | NPC328806 |
0.8125 | Intermediate Similarity | NPC17892 |
0.8125 | Intermediate Similarity | NPC36985 |
0.7917 | Intermediate Similarity | NPC322594 |
0.7917 | Intermediate Similarity | NPC320249 |
0.7812 | Intermediate Similarity | NPC324390 |
0.75 | Intermediate Similarity | NPC317639 |
0.7453 | Intermediate Similarity | NPC329277 |
0.7396 | Intermediate Similarity | NPC89051 |
0.7396 | Intermediate Similarity | NPC43246 |
0.7315 | Intermediate Similarity | NPC155087 |
0.7315 | Intermediate Similarity | NPC149843 |
0.7172 | Intermediate Similarity | NPC315063 |
0.7083 | Intermediate Similarity | NPC106780 |
0.7073 | Intermediate Similarity | NPC318142 |
0.7059 | Intermediate Similarity | NPC324516 |
0.7059 | Intermediate Similarity | NPC318166 |
0.7033 | Intermediate Similarity | NPC315806 |
0.703 | Intermediate Similarity | NPC327344 |
0.687 | Remote Similarity | NPC313813 |
0.6634 | Remote Similarity | NPC163352 |
0.6634 | Remote Similarity | NPC210456 |
0.66 | Remote Similarity | NPC325723 |
0.6458 | Remote Similarity | NPC329077 |
0.6423 | Remote Similarity | NPC284651 |
0.6354 | Remote Similarity | NPC469972 |
0.6337 | Remote Similarity | NPC71339 |
0.6337 | Remote Similarity | NPC112842 |
0.6038 | Remote Similarity | NPC171116 |
0.59 | Remote Similarity | NPC325902 |
0.5827 | Remote Similarity | NPC177169 |
0.5786 | Remote Similarity | NPC232408 |
0.5786 | Remote Similarity | NPC64705 |
0.5755 | Remote Similarity | NPC211820 |
0.5755 | Remote Similarity | NPC251233 |
0.5755 | Remote Similarity | NPC318590 |
0.5736 | Remote Similarity | NPC315058 |
0.5714 | Remote Similarity | NPC317746 |
0.5669 | Remote Similarity | NPC245534 |
0.5641 | Remote Similarity | NPC314398 |
0.5641 | Remote Similarity | NPC314413 |
0.5641 | Remote Similarity | NPC239705 |
0.5612 | Remote Similarity | NPC186619 |
0.5606 | Remote Similarity | NPC313962 |
0.5603 | Remote Similarity | NPC274384 |
0.5603 | Remote Similarity | NPC89147 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC120887 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.967 | High Similarity | NPD1454 | Phase 3 |
0.967 | High Similarity | NPD1455 | Phase 3 |
0.9091 | High Similarity | NPD9604 | Approved |
0.9091 | High Similarity | NPD9602 | Phase 3 |
0.9091 | High Similarity | NPD9603 | Phase 3 |
0.8969 | High Similarity | NPD6946 | Approved |
0.875 | High Similarity | NPD9601 | Approved |
0.8696 | High Similarity | NPD9585 | Discontinued |
0.8409 | Intermediate Similarity | NPD9600 | Approved |
0.8381 | Intermediate Similarity | NPD3138 | Phase 3 |
0.837 | Intermediate Similarity | NPD9553 | Approved |
0.837 | Intermediate Similarity | NPD301 | Discontinued |
0.837 | Intermediate Similarity | NPD9554 | Approved |
0.8333 | Intermediate Similarity | NPD514 | Clinical (unspecified phase) |
0.8302 | Intermediate Similarity | NPD3139 | Phase 3 |
0.8229 | Intermediate Similarity | NPD9639 | Clinical (unspecified phase) |
0.8222 | Intermediate Similarity | NPD9572 | Clinical (unspecified phase) |
0.8191 | Intermediate Similarity | NPD267 | Discontinued |
0.8111 | Intermediate Similarity | NPD9573 | Phase 2 |
0.8105 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.7938 | Intermediate Similarity | NPD215 | Discontinued |
0.7849 | Intermediate Similarity | NPD9555 | Phase 2 |
0.7778 | Intermediate Similarity | NPD9427 | Approved |
0.7677 | Intermediate Similarity | NPD6948 | Phase 3 |
0.7624 | Intermediate Similarity | NPD192 | Phase 2 |
0.7524 | Intermediate Similarity | NPD3128 | Phase 3 |
0.7453 | Intermediate Similarity | NPD3129 | Phase 3 |
0.7444 | Intermediate Similarity | NPD9407 | Approved |
0.7429 | Intermediate Similarity | NPD4743 | Phase 2 |
0.7404 | Intermediate Similarity | NPD7651 | Approved |
0.7396 | Intermediate Similarity | NPD9581 | Clinical (unspecified phase) |
0.7396 | Intermediate Similarity | NPD9580 | Clinical (unspecified phase) |
0.7391 | Intermediate Similarity | NPD9403 | Discontinued |
0.7339 | Intermediate Similarity | NPD1804 | Phase 2 |
0.7339 | Intermediate Similarity | NPD1805 | Phase 2 |
0.729 | Intermediate Similarity | NPD1428 | Phase 2 |
0.72 | Intermediate Similarity | NPD285 | Discontinued |
0.7128 | Intermediate Similarity | NPD9429 | Discontinued |
0.7115 | Intermediate Similarity | NPD3121 | Phase 2 |
0.7111 | Intermediate Similarity | NPD9405 | Approved |
0.7033 | Intermediate Similarity | NPD9653 | Clinical (unspecified phase) |
0.6957 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.6957 | Remote Similarity | NPD6935 | Phase 3 |
0.6939 | Remote Similarity | NPD9557 | Clinical (unspecified phase) |
0.6923 | Remote Similarity | NPD762 | Discontinued |
0.6893 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
0.6852 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.6789 | Remote Similarity | NPD2633 | Phase 1 |
0.6737 | Remote Similarity | NPD9372 | Phase 2 |
0.6697 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.6636 | Remote Similarity | NPD5789 | Clinical (unspecified phase) |
0.6635 | Remote Similarity | NPD1686 | Approved |
0.6634 | Remote Similarity | NPD1760 | Approved |
0.6602 | Remote Similarity | NPD9565 | Discontinued |
0.6549 | Remote Similarity | NPD6693 | Phase 3 |
0.6531 | Remote Similarity | NPD9556 | Approved |
0.6505 | Remote Similarity | NPD755 | Phase 3 |
0.6476 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6471 | Remote Similarity | NPD6918 | Phase 1 |
0.6465 | Remote Similarity | NPD9561 | Approved |
0.6465 | Remote Similarity | NPD9560 | Approved |
0.6449 | Remote Similarity | NPD2621 | Clinical (unspecified phase) |
0.6422 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.64 | Remote Similarity | NPD9559 | Phase 1 |
0.64 | Remote Similarity | NPD9546 | Phase 2 |
0.6389 | Remote Similarity | NPD502 | Approved |
0.6364 | Remote Similarity | NPD9558 | Phase 3 |
0.6354 | Remote Similarity | NPD9370 | Approved |
0.6337 | Remote Similarity | NPD280 | Approved |
0.6337 | Remote Similarity | NPD9533 | Phase 2 |
0.6327 | Remote Similarity | NPD9369 | Clinical (unspecified phase) |
0.6325 | Remote Similarity | NPD7914 | Suspended |
0.6311 | Remote Similarity | NPD241 | Discontinued |
0.63 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6214 | Remote Similarity | NPD240 | Phase 3 |
0.6214 | Remote Similarity | NPD170 | Approved |
0.6214 | Remote Similarity | NPD9562 | Discovery |
0.6207 | Remote Similarity | NPD284 | Phase 1 |
0.6195 | Remote Similarity | NPD3161 | Clinical (unspecified phase) |
0.6111 | Remote Similarity | NPD501 | Phase 1 |
0.6078 | Remote Similarity | NPD9529 | Phase 1 |
0.6038 | Remote Similarity | NPD841 | Approved |
0.6019 | Remote Similarity | NPD239 | Phase 2 |
0.6019 | Remote Similarity | NPD238 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD7761 | Suspended |
0.598 | Remote Similarity | NPD9535 | Phase 2 |
0.598 | Remote Similarity | NPD9534 | Phase 2 |
0.5948 | Remote Similarity | NPD1385 | Discontinued |
0.5926 | Remote Similarity | NPD251 | Approved |
0.5816 | Remote Similarity | NPD9347 | Approved |
0.5816 | Remote Similarity | NPD9346 | Approved |
0.5806 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.5699 | Remote Similarity | NPD9211 | Clinical (unspecified phase) |
0.566 | Remote Similarity | NPD9654 | Phase 2 |
PubChem CID   | 6132 |
ChEMBL   | CHEMBL425252 |
ZINC   |
Molecular Weight:   | 403.02 |
ALogP:   | -2.6039 |
MLogP:   | 0.69 |
XLogP:   | -3.493 |
# Rotatable Bonds:   | 12 |
Polar Surface Area:   | 242.28 |
# H-Bond Aceptor:   | 14 |
# H-Bond Donor:   | 7 |
# Rings:   | 2 |
# Heavy Atoms:   | 25 |